EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study

Angela Manzanares, Jacobo Pardo-Seco, Irene Rivero-Calle, Ana Dacosta-Urbieta, Narmeen Mallah, María-Isolina Santiago-Pérez, Olaia Pérez-Martínez, María-Teresa Otero-Barrós, Nuria Suárez-Gaiche, Rolf Kramer, Jing Jin, Leticia Platero-Alonso und 10 weitere

European Journal of Pediatrics · 02.05.2025 · 184 (5)

DOI: 10.1007/s00431-025-06151-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Pediatrics, online erschienen am 02.05.2025. Verfasst von Angela Manzanares und 21 weiteren Autor:innen. Beteiligte Einrichtung: Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC),…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antiviral Agents, Hospitalization, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Universidade de Santiago de Compostela.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As part of the NIRSEGAL study ( https://www.nirsegal.es/en ), we present the clinical characteristics and course of respiratory syncytial virus (RSV)-related low respiratory tract infection (LRTI) hospitalizations in infants eligible for nirsevimab administration during the 2023–2024 season. Infants eligible for nirsevimab immunization (born between 1 April, 2023, and 30 March, 2024) who were hospitalized due to RSV-related LRTI between September 25, 2023, and April 15, 2024, in a hospital from the Galician Public Health system were included. Clinical and demographic characteristics of RSV-related LRTI hospitalizations were analyzed, with comparisons made between breakthrough cases (those immunized with nirsevimab) and non-breakthrough cases. During the study period, 69 RSV-related LRTI hospitalizations were recorded, with a median hospital stay of 4 (interquartile range (IQR) 3–6) days; 65.2% ( N = 45) were breakthrough cases. The median age was 2.7 (IQR 1.5–5.2) months, and more than half of them ( N = 39, 56.5%) were male. The incidence of cases was parallel to the RSV epidemic curve, suggesting no waning of nirsevimab efficacy. Of the total hospitalizations, 16 infants (23.2%) had a high-risk condition, 44 (63.8%) needed oxygen support, 15 (21.7%) were admitted to the intensive care unit (ICU), and 11 (15.9%) received non-invasive mechanical ventilation (NIMV). No statistically significant differences were observed in these characteristics when comparing breakthrough and non-breakthrough cases.

Conclusion

In the nirsevimab era, a substantial proportion of children who were hospitalized for RSV-related LRTI needed oxygen support, NIMV, and ICU admission. Clinical characteristics, timing, and outcomes were comparable between breakthrough and non-breakthrough cases.

Trial registration

The NIRSE-GAL study protocol was registered on ClinicalTrials.gov (NCT06180993). What is Known :• Nirsevimab, a long-acting monoclonal antibody, has shown high effectiveness in preventing RSV-related hospitalizations and has been included in some European countries’ immunization programs . What is New: • During the first RSV season after the universal implementation of nirsevimab in Galicia (Spain), a large proportion of hospitalized infants had high-risk conditions, yet disease severity markers (oxygen need, ICU admission, NIVM) were comparable between breakthrough and non-breakthrough cases .• No signal of waning protection over time was observed among breakthrough cases, reinforcing the potential value of early, season-wide immunization .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntiviral AgentsHospitalizationRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsFemaleHumansInfantMaleSpain

Stichwörter der Autor:innen

Breakthrough casesImmunizationInfantsLow respiratory tract infection (LRTI)NirsevimabRespiratory syncytial virus (RSV)

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral Agents

Autor:innen und Institutionen

  • Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago (SERGAS) and University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain.
  • Genetics, Vaccines and Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain.
  • WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Galicia, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
  • Genética de Poblaciones en Biomedicina (GenPoB) Research Group, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), Galicia, Spain.
  • Department of Preventive Medicine, University of Santiago de Compostela (USC), Santiago de Compostela, Galicia, Spain.

Förderung

  • Sanofi
  • Universidade de Santiago de Compostela

Zitieren

APA

Manzanares, A., Pardo-Seco, J., Rivero-Calle, I., Dacosta-Urbieta, A., Mallah, N., Santiago-Pérez, M. I., Pérez-Martínez, O., Otero-Barrós, M. T., Suárez-Gaiche, N., Kramer, R., Jin, J., Platero-Alonso, L., Alvárez-Gil, R. M., Ces-Ozores, O. M., Nartallo-Penas, V., Mirás-Carballal, S., Piñeiro-Sotelo, M., González-Pérez, J. M., Rodríguez-Tenreiro-Sánchez, C., …, & Martinón-Torres, F. (2025). Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study. European Journal of Pediatrics, 184(5). https://doi.org/10.1007/s00431-025-06151-3

Vancouver

Manzanares A, Pardo-Seco J, Rivero-Calle I, Dacosta-Urbieta A, Mallah N, Santiago-Pérez MI, et al. Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study. European Journal of Pediatrics. 2025;184(5). doi:10.1007/s00431-025-06151-3

BibTeX
@article{Manzanares2025,
  author = {Manzanares, Angela and Pardo-Seco, Jacobo and Rivero-Calle, Irene and Dacosta-Urbieta, Ana and Mallah, Narmeen and Santiago-Pérez, María-Isolina and Pérez-Martínez, Olaia and Otero-Barrós, María-Teresa and Suárez-Gaiche, Nuria and Kramer, Rolf and Jin, Jing and Platero-Alonso, Leticia and Alvárez-Gil, Rosa-María and Ces-Ozores, Olga-María and Nartallo-Penas, Victoria and Mirás-Carballal, Susana and Piñeiro-Sotelo, Marta and González-Pérez, Juan-Manuel and Rodríguez-Tenreiro-Sánchez, Carmen and Salas, Antonio and Durán-Parrondo, Carmen and Martinón-Torres, Federico},
  title = {Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study},
  journal = {European Journal of Pediatrics},
  year = {2025},
  volume = {184},
  number = {5},
  doi = {10.1007/s00431-025-06151-3}
}
Kostenlos starten →